Elevated Lipoprotein-Associated Phospholipase A2 is Valuable in Prediction of Coronary Slow Flow in Non-ST-Segment Elevation Myocardial Infarction Patients

Liang, Qi; Lei, Xinjun; Huang, Xin; Fan, Lihong; Yu, Haitao

doi:10.1016/j.cpcardiol.2020.100596

Cited by 4 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with primary CSF, defined as slow coronary filling in absence of stenosis, cTFC has been confirmed to be positively correlated with multitudes of inflammatory cytokines including hs-CRP, IL-6 [27,28] and Interferon-γ receptor 1 [29]. In patients with NSTEMI, elevated lipoprotein-associated phospholipase A2 which acts as a vascular specific inflammatory cytokine could predict post-PCI CSF occurrence [30]. Besides, a small amount of study reported that adipocytokines played a protective role in patients with CAD who experienced CSF [31,32].…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Elevated levels of sIL-2R, TNF-α and hs-CRP are independent risk factors for post percutaneous coronary intervention coronary slow flow in patients with non-ST segment elevation acute coronary syndrome

Wang

et al. 2022

Int J Cardiovasc Imaging

View full text Add to dashboard Cite

To evaluate the association between circulating levels of inflammatory cytokines and the occurrence of post-percutaneous coronary intervention (PCI) coronary slow flow (CSF) in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS). CSF after PCI commonly occurs and implies poor outcomes, while the determinants of post-PCI CSF in patients with NSTE-ACS remain controversial. In this multicenter case control study, 176 patients diagnosed with NSTE-ACS and with post-PCI CSF occurred composed of CSF group, while 352 matched NSTE-ACS patients composed control group. Corrected thrombolysis in myocardial infarction frame count (cTFC), circulating levels of inflammatory cytokines and PCI related parameters were analyzed using Logistic regression models. Among 528 patients with median age of 67 (59–76) and male proportion of 65.5%, 176 (35.0%) patients had occurrence of post-PCI CSF defined as cTFC ≥ 24. Patients with CSF presented more intense inflammatory activity revealed by higher levels of white blood cell, high-sensitivity C-reactive protein (hs-CRP), interleukin-1ß (IL-1ß), soluble IL-2 receptor (sIL-2R), IL-6, IL-8, IL-10 and tumor necrosis factor-α (TNF-α), while PCI related parameters were comparable. Correlation analysis showed cTFC was positively correlated with those inflammatory cytokines. Logistic regression model indicates that hs-CRP (odds ratio (OR) = 3.038, 95% confidence interval (CI) 1.545–5.975), sIL-2R (OR = 2.103, 95% CI 1.959–4.026) and TNF-α (OR = 3.708, 95% CI 1.426–9.641) were valuable predictors for CSF occurrence. Elevated circulating levels of inflammatory cytokine including hs-CRP, sIL-2R and TNF-α rather than PCI related parameters could predict post-PCI CSF in patients with NSTE-ACS.

show abstract

Section: Discussionmentioning

confidence: 95%

“…The peri-procedure data were analyzed between groups as displayed in Table 2. The median cTFC of patients with CSF and non-CSF was 27 [25][26][27][28][29][30] and 19 [16][17][18][19][20][21] respectively. CSF occurrence presented comparably among 3 culprit vessels.…”

Section: Angiographic Findings and Pci Related Parametersmentioning

confidence: 99%

Elevated levels of sIL-2R, TNF-α and hs-CRP are independent risk factors for post percutaneous coronary intervention coronary slow flow in patients with non-ST segment elevation acute coronary syndrome

Wang

et al. 2022

Int J Cardiovasc Imaging

View full text Add to dashboard Cite

show abstract

“…It was defined as the first frame when the contrast agent touched the two medial walls of the coronary artery and the diameter of the stained vessel was more than 70%, and it was defined as the last frame when the contrast agent reached the end of each branch of the coronary artery [ 8 ]. CSF/NRF was defined as a corrected TIMI frame count (cTFC) of >27 frames for the target vessel during PCI, and patients with coronary artery dissection [ 9 ] were excluded [ 10 ]. Patients with CSF/NRF were included in the CSF/NRF group and other patients (cTFC ≤27 frames) in the control group.…”

Section: Methods and Groupingmentioning

confidence: 99%

Predictive Value of Soluble Growth Stimulator Gene 2 Protein for Coronary Slow Flow/No-Reflow in ST-Elevation Myocardial Infarction Patients Receiving Percutaneous Coronary Intervention

Chang

Luan

et al. 2022

Journal of Interventional Cardiology

View full text Add to dashboard Cite

Background. Soluble growth stimulator gene 2 protein (sST2) is associated with heart failure and myocardial infarction; however, the predictive value of plasma sST2 level for coronary slow flow/no-reflow (CSF/NRF) is unclear. This study aimed to explore the predictive value of plasma sST2 levels for CSF/NRF in patients with ST-elevation myocardial infarction (STEMI) who underwent emergency percutaneous coronary intervention (PCI). Methods. A total of 242 STEMI patients who underwent emergency PCI at our hospital between November 2020 and July 2021 were enrolled in this study. According to the postprocedural procedure, these patients were divided into the CSF/NRF and control groups. Clinical data were collected from both groups and were used to explore the predictive value of serum sST2 levels for CSF/NRF. Results. Of the total 242 patients, CSF/NRF was observed in 50 patients (20.7%). Statistically significant differences ( P < 0.05 ) were observed in age, diabetes mellitus, sST2 level, neutrophil-to-lymphocyte ratio (NLR), fasting blood sugar, preprocedural blood pressure, intraprocedural hypotension, N-terminal pro-B-type natriuretic peptide, MB isoenzyme of creatine kinase (CK-MB), and cardiac troponin I (cTNI). Multivariate analysis showed that the sST2 level, NLR, and intraoperative hypotension were independent risk factors for CSF/NRF. ROC curve analysis showed that the sensitivity and specificity of the sST2 level for predicting CSF/NRF were 68.0% and 75.5%, respectively, when the sST2 level was more than 64.6 ng/mL (AUC = 0.780, 95% CI: 1.003–1.020, P = 0.009 ). Conclusion. For STEMI patients, preprocedural sST2 levels significantly correlated with CSF/NRF occurring in PCI. sST2 level is a potential predictor for CSF/NRF occurrence.

show abstract

“…Unlike systemic inflammatory factors such as hs-CRP and ILs, lipoprotein associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory factor with a relatively stable concentration that is not affected by infection. The level of Lp-PLA2 thus directly and accurately reflects the extent of intravascular inflammation [ 9 ]. However, few studies have explored the correlation between Lp-PLA2 levels and CMBs.…”

Section: Introductionmentioning

confidence: 99%

Correlation of lipoprotein-associated phospholipase A2 and cerebral microbleeds in patients with acute ischaemic stroke

et al. 2022

View full text Add to dashboard Cite

Background and aims Cerebral microbleeds (CMBs) increase the risk of stroke occurrence and recurrence,and affect the prognosis of stroke patients. Therefore, identifying biological markers that predict CMBs after stroke is urgently needed. This study explored whether high levels of lipoprotein-associated phospholipase A2(Lp-PLA2) are associated with an increased risk of CMBs in patients with acute ischaemic stroke (AIS). Methods From April 2020 to October 2021, we enrolled 242 patients with AIS. At admission, the plasma levels of Lp-PLA2 were measured in all patients as well as the number of CMBs and white matter lesions. According to the results of the Susceptibility Weighted Imaging (SWI), the patients were divided into a CMB group and a no-CMB group. The groups were compared with univariate and multivariate analyses to clarify the correlation between Lp-PLA2 levels and CMBs, and the optimal cut-off value of Lp-PLA2 that predicted CMBs was determined from the receiver-operating characteristic curve. Results CMBs were detected in 71 (29.3%) of the 242 AIS patients. The median Lp-PLA2 level was 182.79 ng/ml. Using the 1st quartile of Lp-PLA2 levels (the lowest levels) as the reference group, univariate logistic regression analysis showed that individuals in the 4th quartile (the highest levels) had a higher risk of CMBs (odds ratio [OR] = 1.460, 95% confidence interval [CI]: 1.188–1.795, P = 0.000). This correlation persisted after adjusting for relevant risk factors (OR = 1.370, 95% CI: 1.096–1.713, P = 0.006). The optimal cut-off value of Lp-PLA2 that predicted the occurrence of CMBs was 184.36 ng/ml; at this threshold, the sensitivity was 69.0%, and the specificity was 60.2%. Conclusions Our data suggest that a high level of Lp-PLA2 in patients with AIS is a potential risk factor for CMBs.

show abstract

Elevated Lipoprotein-Associated Phospholipase A2 is Valuable in Prediction of Coronary Slow Flow in Non-ST-Segment Elevation Myocardial Infarction Patients

Cited by 4 publications

References 35 publications

Elevated levels of sIL-2R, TNF-α and hs-CRP are independent risk factors for post percutaneous coronary intervention coronary slow flow in patients with non-ST segment elevation acute coronary syndrome

Elevated levels of sIL-2R, TNF-α and hs-CRP are independent risk factors for post percutaneous coronary intervention coronary slow flow in patients with non-ST segment elevation acute coronary syndrome

Predictive Value of Soluble Growth Stimulator Gene 2 Protein for Coronary Slow Flow/No-Reflow in ST-Elevation Myocardial Infarction Patients Receiving Percutaneous Coronary Intervention

Correlation of lipoprotein-associated phospholipase A2 and cerebral microbleeds in patients with acute ischaemic stroke

Contact Info

Product

Resources

About